Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,941 to 2,960 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR) | 44 of 1,236 39 of 1,255 | 0.5 points -1.0 to 1.9 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI | 116 of 1,236 106 of 1,255 | 0.9 points -1.3 to 3.2 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI | 107 of 1,236 96 of 1,255 | 1.0 points -1.1 to 3.2 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR) | 185 of 1,236 161 of 1,255 | 2.1 points -0.6 to 4.9 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular) | 22 of 1,236 22 of 1,255 | 0.0 points -1.0 to 1.1 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI) | 104 of 1,236 86 of 1,255 | 1.6 points -0.5 to 3.7 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE) | 146 of 1,236 121 of 1,255 | 2.2 points -0.3 to 4.6 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Coronary PCI Guided by OCT vs Coronary PCI Guided by Angiography: deaths from any cause | 33 of 1,233 44 of 1,254 | -0.8 points -2.2 to 0.5 | 2,487 | NCT03507777 ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI) |
| Coronary PCI Guided by OCT vs Coronary PCI Guided by Angiography: serious adverse events | 405 of 1,233 411 of 1,254 | 0.1 points -3.6 to 3.8 | 2,487 | NCT03507777 ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI) |
| Fluticasone Maintenance vs Fluticasone Withdrawal: serious adverse events | 292 of 1,243 300 of 1,242 | -0.7 points -4.0 to 2.7 | 2,485 | NCT00975195 Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease |
| Daprodustat vs rhEPO: Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52) | 903 of 1,238 866 of 1,247 | 3.5 points -0.1 to 7.0 | 2,485 | NCT02879305 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) |
| ICD Implant Without Defibrillation Testing vs ICD Implant With Defibrillation Testing: Perioperative Complication Rate | 69 of 1,236 81 of 1,242 | -0.9 points -2.8 to 1.0 | 2,478 | NCT00800384 Shockless Implant Evaluation |
| Treatment vs Control: deaths from any cause | 134 of 1,245 127 of 1,225 | 0.4 points -2.0 to 2.8 | 2,470 | NCT02604264 Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap |
| Heterosexual and MSM Males vs Females: serious adverse events | 23 of 1,394 26 of 1,075 | -0.8 points -2.0 to 0.3 | 2,469 | NCT01651949 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) |
| Absorb BVS vs XIENCE: Number of Participants With Rehospitalization | 544 of 1,226 525 of 1,242 | 2.1 points -1.8 to 6.0 | 2,468 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Treatment Prevention for Secondary CV vs Cardiovascular Polypill: deaths from any cause | 117 of 1,229 115 of 1,237 | 0.2 points -2.1 to 2.5 | 2,466 | NCT02596126 Secondary Prevention of Cardiovascular Disease in the Elderly Trial |
| Treatment Prevention for Secondary CV vs Cardiovascular Polypill: serious adverse events | 220 of 1,229 248 of 1,237 | -2.1 points -5.2 to 0.9 | 2,466 | NCT02596126 Secondary Prevention of Cardiovascular Disease in the Elderly Trial |
| Folic Acid 4 mg vs Placebo: serious adverse events | 227 of 1,227 195 of 1,236 | 2.7 points -0.3 to 5.7 | 2,463 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF) | 171 of 1,219 134 of 1,241 | 3.2 points 0.6 to 5.8 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI) | 126 of 1,219 104 of 1,241 | 2.0 points -0.3 to 4.3 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=148"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=148
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02173379-6c8c8d00",
"title": "Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)",
"summary": "44 of 1236 against 39 of 1255; risk difference 0.5 points, 95% interval -1.0 to 1.9; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-6c8c8d00",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2491,
"risk_difference": {
"value": 0.004523008290462746,
"lower": -0.009768931621627756,
"upper": 0.018970160745002677
},
"group_1": "44 of 1,236",
"group_2": "39 of 1,255",
"difference": "0.5 points",
"interval": "-1.0 to 1.9",
"trial_title": "Absorb IV Randomized Controlled Trial"
},
{
"id": "NCT02173379-780d0b2a",
"title": "Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI",
"summary": "116 of 1236 against 106 of 1255; risk difference 0.9 points, 95% interval -1.3 to 3.2; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-780d0b2a",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2491,
"risk_difference": {
"value": 0.009388981291661824,
"lower": -0.013060164339266024,
"upper": 0.03192196220472632
},
"group_1": "116 of 1,236",
"group_2": "106 of 1,255",
"difference": "0.9 points",
"interval": "-1.3 to 3.2",
"trial_title": "Absorb IV Randomized Controlled Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=149",
"request_id": "19jEGEPAa6MTOWIN"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant